Humanigen, Inc. (HGENQ)

Market Cap	23.82K
Revenue (ttm)	1.70M
Net Income (ttm)	-53.63M
Shares Out	119.08M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,023
Open	0.0020
Previous Close	0.0002
Day's Range	0.0002 - 0.0020
52-Week Range	n/a
Beta	-1.05
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About HGENQ

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2013
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: HGENQ
• Website: https://www.humanigen.com

Financial Performance

In 2022, Humanigen's revenue was $2.51 million, a decrease of -30.07% compared to the previous year's $3.60 million. Losses were -$70.73 million, -70.11% less than in 2021.